“Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)”. 2020. SKIN The Journal of Cutaneous Medicine 4 (5): s49. https://doi.org/10.25251/skin.4.supp.48.